NCT01367613View on ClinicalTrials.gov

Open-Label Treatment Extension of Protocol MNTX 302

PHASE3CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

January 31, 2006

Study Completion Date

January 31, 2006

Conditions
Terminal Illness
Interventions
DRUG

SC Methylnaltrexone

Trial Locations (1)

10591

Progenics Pharmaceuticals, Inc., Tarrytown

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY

NCT01367613 - Open-Label Treatment Extension of Protocol MNTX 302 | Biotech Hunter | Biotech Hunter